CDKN2B and meningioma: The update in 2021 included molecular factors that significantly shorten survival and increase recurrence, such as meningiomas with a telomerase reverse transcriptase (TERT) promoter mutation or homozygous deletions in the cell cycle regulator genes CDKN2A and/or CDKN2B [6].